U.S. Hematology Diagnostics Market Summary

The U.S. hematology diagnostics market size was estimated at USD 2.12 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. This growth is primarily attributed to the rising prevalence of hematological disorders, which are becoming more common due to aging populations and lifestyle-related factors such as sedentary habits, poor diet, and increasing incidences of chronic diseases. These factors have led to greater reliance on diagnostic testing to ensure timely detection and management of such conditions. Moreover, the integration of advanced diagnostic technologies, including flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS), has significantly improved the accuracy, sensitivity, and efficiency of diagnostic outcomes, driving adoption across healthcare settings. With the elderly population more vulnerable to hematological disorders, there is a growing demand for timely diagnostics to monitor age-associated conditions such as myelodysplastic syndromes and thrombocytopenia.

The prevalence of hematological conditions such as anemia, leukemia, lymphoma, and thrombosis is further fueling demand for diagnostic testing in the U.S. According to the American Cancer Society’s projections for 2024, around 62,770 new leukemia cases were anticipated in the country, leading to approximately 23,670 deaths. Among these, acute myeloid leukemia (AML) alone was projected to account for nearly 20,800 new cases, predominantly affecting adults, and resulting in around 11,220 deaths. Although AML constitutes only about 1% of all cancer types, it remains one of the most common forms of leukemia among adults. The average age of diagnosis is around 68 years, highlighting its predominance in older populations. Occurrences in children are comparatively rare, and while AML incidence rates are slightly higher among men, both men and women have an equal lifetime risk of roughly 0.5%.

Key Market Trends & Insights

• The consumables segment dominated the hematology diagnostics market in 2023, accounting for approximately 65% of the revenue share, and is forecasted to grow at the fastest CAGR of 5.4% during the study period. The demand for consumables is rising sharply, given the continuous requirement for reagents, stains, and calibration products to ensure consistent and accurate results. Hospitals, diagnostic laboratories, and research institutions rely heavily on consumables to maintain the high throughput of tests necessitated by increasing disease prevalence, making this segment indispensable for the overall market.
• From an end-use perspective, hospitals held the largest share of the U.S. hematology diagnostics market in 2023. This dominance is attributed to the expanding healthcare infrastructure, the growing burden of hematological disorders requiring comprehensive diagnostic support, and technological advancements that enable hospitals to deliver rapid and reliable testing. Hospitals are also better equipped with advanced diagnostic devices and have access to highly skilled healthcare professionals, making them the preferred choice for accurate hematological evaluations.
• By test type, the white blood cell (WBC) test segment held the largest revenue share in 2023 and is anticipated to register the fastest CAGR over the forecast period. WBC tests play a crucial role in diagnosing infections, autoimmune disorders, and hematological malignancies, as well as in monitoring immune system health. Their rising demand reflects the importance of timely and accurate evaluation of white blood cell counts for both routine health checkups and disease management.

Order a free sample PDF of the U.S. Hematology Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 2.12 billion
• 2030 Projected Market Size: USD 3.07 billion
• CAGR (2024 - 2030): 5.3%

Key Companies & Market Share Insights

Key players shaping the competitive landscape of the U.S. hematology diagnostics market include Beckman Coulter Diagnostics; Siemens Healthineers; Mindray Medical International Limited; F. Hoffmann-La Roche Ltd.; Sysmex Corporation; Beckman Coulter, Inc.; and HORIBA, Ltd. Siemens Healthineers plays a critical role with its broad portfolio, offering services in diagnostic and therapeutic imaging, laboratory diagnostics, molecular medicine, digital health solutions, and enterprise services. It caters to diverse healthcare providers such as hospitals, clinics, laboratories, physicians, research institutes, public health organizations, government bodies, insurers, and pharmaceutical companies. Similarly, Abbott contributes significantly to the market through its wide range of healthcare products, spanning diagnostic systems, branded generic drugs, and nutritional products. Abbott also provides advanced medical devices across multiple categories, including electrophysiology, vascular rhythm management, structural heart solutions, neuromodulation, and devices for heart failure treatment, supporting comprehensive patient care.

Key Players

• Siemens Healthineers AG
• BIOMEDOMICS INC.
• Abbott
• Danaher
• Sysmex Corporation
• Beckman Coulter, Inc.
• F. Hoffmann-La Roche Ltd
• HORIBA, Ltd.
• Bio-Rad Laboratories, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. hematology diagnostics market is expanding steadily, supported by rising disease prevalence, growing elderly populations, and increasing adoption of advanced diagnostic technologies. With consumables driving consistent demand and hospitals serving as the primary end-use segment, the market reflects strong integration of innovative testing solutions into clinical practice. Tests such as WBC counts remain central to identifying a wide spectrum of conditions, ensuring timely treatment decisions. Major players like Siemens Healthineers, Abbott, and Sysmex are shaping industry advancements through innovation and service expansion. Looking ahead, the market is expected to witness sustained growth, improving healthcare outcomes across hematological conditions.